FINWIRES · TerminalLIVE
FINWIRES

研究快讯:BFH 第一季度:贷款增长回归正轨,每股收益飙升 50%,资本回报加速。

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:BFH公布了强劲的2026财年第一季度业绩,每股收益(EPS)为4.15美元,同比增长50%,超出市场预期0.99美元;营收增长5%至10.2亿美元,高于华尔街预期的9.97亿美元。业绩增长主要得益于定价优化、融资成本降低以及信贷销售额强劲增长(增长7%至65亿美元,连续第六个季度实现增长)。我们认为,贷款增长的恢复是一个关键的转折点,在经历了几个季度的下滑后,期末贷款额增长2%至181亿美元,这主要得益于新合作伙伴的加入以及年轻群体购物活动的增加。资产负债表优化措施包括通过1.5亿美元的股票回购和上限期权解除,注销了350万股(占流通股的8%),并增加了6亿美元的授权额度。信贷质量趋势依然令人瞩目,违约率下降 34 个基点至 5.59%,净损失率改善 83 个基点至 7.33%,同时 CET1 比率增强至 13.3%,每股有形账面价值增长 26% 至 61.57 美元。

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF